Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - BridGene Biosciences/Galapagos

Next Previous
X
Search
Drug Profile

Research programme: small molecule therapeutics - BridGene Biosciences/Galapagos

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BridGene Biosciences; Galapagos NV
  • Developer BridGene Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein-protein interaction inhibitors; Rho GTP-binding protein inhibitors; Transcription factor inhibitors; WDR5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Jan 2024 BridGene Biosciences and Galapagos agree to co-promote and co-develop small molecule therapeutics for Cancer
  • 05 Jan 2022 BridGene Biosciences plans to file an IND application with the US FDA for Cancer in 2023
  • 30 Sep 2021 Preclinical trials in Cancer in USA (unspecified route) before September 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top